Zydus said the vaccine, which is a three-course regimen, showed safety and efficacy in a late-stage trial with more than 28,000 volunteers across the country, including about 1,000 subjects in the 12-18-year age group.
from Top India News- News18.com https://ift.tt/2SDmkF0
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment